Inferra AI / Company / AGIO
Agios Pharmaceuticals, Inc..
AGIO · Health Care
Last earnings Jul 30, 2026
Key results
Revenuequarter
$12.5 million
htm EX-99.1 Document Exhibit 99.1 Agios Reports Second Quarter 2025 Financial Results and Provides Business Update $12.5 million in second quarter PYRUKYND (mitapivat) net revenues ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securities PYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025 Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Second Quarter 2025 and Recent Corporate Highlights Commercial Performance PYRUKYND (mitapivat) Generated $12.5 million in net revenue for the second quarter of 2025, compared to $8.6 million in the second quarter of 2024.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Net product revenue from sales of PYRUKYND for the second quarter of 2025 was $12.5 million, compared to $8.6 million for the second quarter of 2024.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
AI analysis
Q2 2025 · reported Jul 31, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance · company-stated
No guidance located in the held release
Capital allocation
If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts, or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
Treasuries 251,421 251,421 Government securities 145,777 145,777 Corporate debt securities 467,985 467,985 Total marketable securities 865,183 865,183 Total cash equivalents and marketable securities $ 30,098 $ 873,826 $ $ 903,924 Cash equivalents and marketable securities have been initially valued at the transaction price and are subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other observable market data.
Event summary
In the second quarter, we made progress advancing our early- and mid-stage pipeline and remain on track to deliver topline results of the RISE UP Phase 3 trial for PYRUKYND in sickle cell disease by the end of the year
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
If we are unable to raise additional funds through equity or debt financings, we may be required to delay, limit, reduce or terminate product development or future commercialization efforts, or grant rights to develop and market products or product candidates that we would otherwise prefer to develop and market ourselves.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Treasuries 251,421 251,421 Government securities 145,777 145,777 Corporate debt securities 467,985 467,985 Total marketable securities 865,183 865,183 Total cash equivalents and marketable securities $ 30,098 $ 873,826 $ $ 903,924 Cash equivalents and marketable securities have been initially valued at the transaction price and are subsequently valued, at the end of each reporting period, utilizing third-party pricing services or other observable market data.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Marketable Securities Our marketable securities are classified as available-for-sale pursuant to ASC 320, Investments Debt and Equity Securities , and are recorded at fair value.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Treasuries $ 96,509 $ 102 $ ( 8 ) $ 96,603 Government securities 88,570 4 ( 61 ) 88,513 Corporate debt securities 332,977 100 ( 264 ) 332,813 Total current 518,056 206 ( 333 ) 517,929 Non-current: U.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Treasuries 129,738 648 ( 1 ) 130,385 Government securities 54,527 31 ( 10 ) 54,548 Corporate debt securities 124,767 346 ( 33 ) 125,080 Total non-current 309,032 1,025 ( 44 ) 310,013 Total marketable securities $ 1,073,115 $ 2,254 $ ( 61 ) $ 1,075,308 As of June 30, 2026 and December 31, 2025, we held both current and non-current investments.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
As of June 30, 2026 and December 31, 2025, we held 134 and 37 debt securities, respectively, that were in an unrealized loss position for less than one year.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Strategy & priorities
(Nasdaq AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced financial results and updates for the second quarter ended June 30, 2025.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Collectively, our progress reflects our continued focus on delivering innovative medicines with the potential to transform the lives of those affected by rare diseases and deliver long-term shareholder value.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
, a rapidly growing European specialty pharmaceutical company focused on rare diseases, to distribute and commercialize PYRUKYND across the European Economic Area, the United Kingdom and Switzerland.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Such forward-looking statements include those regarding the potential benefits of PYRUKYND (mitapivat), tebapivat, AG-236 and AG-181 Agios plans, strategies and expectations for its preclinical, clinical and commercial advancement of its drug development, including PYRUKYND , tebapivat, AG-236 and AG-181 Agios use of proceeds from the transaction with Royalty Pharma potential U.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Risks & headwinds
Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios current expectations and beliefs.
SEC original ↗Agios Pharmaceuticals, Inc.. — Earnings release (8-K exhibit)EX-99Jul 31, 2025
Readers are cautioned that these forward-looking statements are predictions and are subject to risks, uncertainties and assumptions that are difficult to predict.
SEC original ↗Agios Pharmaceuticals, Inc.. — 10-Q Quarterly report10-QJul 30, 2026
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
31 documentsEarnings releases
11 documentsPresentations
0 documentsNo presentations for Agios Pharmaceuticals, Inc.. are held in this edition of the library.
Transcripts
0 documentsNo transcripts for Agios Pharmaceuticals, Inc.. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.